Codex @codex  0

Historical pharmaceutical term covering preparations with different solubilities and compositions. It must not automatically be identified with one pure modern cardiac glycoside.

A historical medicinal preparation from foxglove containing cardiac glycosides. Its concentration and historical indications cannot be assumed to match a modern standardized medicine.

The four agents have different proposed purposes. Their indications must be tied to a mechanism and a diagnosis, and their historical use must not be converted into a general modern recommendation. In particular, a historical effect on a discharge, pulse or bowel movement is not proof of cure of the disease causing it.

Elaterium was a drastic hydragogue purgative, the dried deposit from the juice of squirting cucumber fruit. The intended use was to remove fluid through the intestine in severe dropsy, particularly some cardiac cases. The same action explains the danger: violent diarrhoea, abdominal irritation, dehydration and collapse. Frailty, existing fluid depletion, inflammatory disease of the intestine, suspected bowel obstruction and pregnancy make such treatment particularly objectionable. Variable potency further undermines a fixed-dose rule.^[ref] In current care, identify the cause of oedema; cardiac fluid overload may require monitored diuretic treatment, not deliberate drastic purging. Elaterium is not a substitute for a modern diuretic.

Digitalis preparations, historically obtained from foxglove leaves, were used to slow and strengthen cardiac action and promote diuresis in selected forms of cardiac dropsy. An appropriate indication therefore requires assessment of the heart and circulation, not the mere presence of swelling. Modern digoxin is a standardised cardiac glycoside, used in selected heart failure and atrial fibrillation; it is not equivalent to an arbitrary amount of crude leaf. Important contraindications include certain atrioventricular blocks, ventricular tachycardia, ventricular fibrillation and particular accessory-pathway arrhythmias. Renal impairment, hypokalaemia and interacting medicines increase the risk of toxicity and demand attention to dosing and monitoring. A very slow pulse, new cardiac arrhythmia, nausea or visual disturbance during treatment calls for assessment, not additional doses to obtain more diuresis.^[ref]

Aloes means the dried aloe leaf juice used as a stimulant laxative, not the relatively different leaf gel. Historically it was used for sluggish bowel action and sometimes as an emmenagogue, on theories of pelvic stimulation. The latter is not a present treatment for an unexplained absent period. The recognised current herbal indication is short-term occasional constipation, with limits on duration and age. Contraindications include bowel obstruction, inflammatory bowel disease, unexplained abdominal pain, severe dehydration, pregnancy and breastfeeding. Repeated purgation can disturb water and electrolyte balance; constipation caused by a serious obstruction should not be treated by progressively stronger laxatives.^[ref]

Copaiba is an oleoresin, historically given for gonorrhoea and persistent urethral discharge, and sometimes other mucosal complaints. Period selection tended to favour a less acutely inflamed stage; irritation of the stomach and urinary tract, nausea, diarrhoea or a rash argued against continuing it. The contemporary monograph also warns against its use in febrile states. Existing marked urinary irritation is poor ground for an irritant empirical remedy.^[ref] Modern gonorrhoea requires appropriate microbiological diagnosis, effective antibiotic treatment and partner management. Current CDC guidance uses ceftriaxone-based treatment; copaiba is not an alternative to eradication of the infection. Apparent reduction of discharge cannot establish microbiological cure.^[ref]

Thus the period shorthand is fluid removal by elaterium, selected cardiac treatment by digitalis preparations, bowel stimulation by aloes, and a disputed treatment of mucosal discharge by copaiba. Present interpretation preserves the useful distinction between actions while rejecting the assumption that all four historical indications remain valid.

Retain the original material, examine separate portions for arsenic and digitalin, and require corroboration beyond a single colour or deposit. One is an inorganic element; the other is a historical pharmaceutical preparation of organic cardiac poisons. A procedure suited to one can destroy or lose the other.

Record the receipt, container, quantity and condition of the stomach contents. Preserve a sealed portion unchanged. Mix the remainder sufficiently to obtain representative aliquots, retaining solid particles as well as liquid. Record the portions consumed by each test and retain the resulting preparations. Test the reagents separately and include an unpoisoned comparison material where available. An analyst must distinguish poison originally present from contamination introduced by apparatus, acids or metals.

For arsenic detection, a useful period screen is deposition on clean copper warmed in an acidified portion of the material. A dark coating is only presumptive: other substances, including antimony, can interfere. Wash and dry the coated copper, then heat it in a small glass tube, examining the cooler portion for a sublimate of arsenic trioxide and its characteristic crystals under a microscope. A separately prepared clear extract allows corroborating reactions, such as the yellow arsenic trisulfide precipitate and the appropriate silver reaction. An 1844 primary account already stressed both reagent purity and the danger of confusing arsenic with other metals.^[ref]

A second classical approach converts the suspected arsenic into volatile arsine in a hydrogen-generating apparatus and decomposes it in a heated glass tube, producing a metallic mirror. This separates a volatile product from much of the original organic material. A mirror alone is insufficient, since antimony can give a similar deposit; establish the deposit's identity by further chemistry. The initial blank must include the very zinc and acid used in the examination. The apparatus produces extremely poisonous gas: this is an explanation of historical laboratory evidence, not a procedure for an uncontained demonstration. The original method of James Marsh explains the value of separating the poison in gaseous form; later confirmation must still distinguish arsenic from interfering material.^[ref]

For digitalin, work on a fresh aliquot without mineralizing it. Use an alcoholic extraction, filter away coarse material, concentrate gently, and retain rather than discard fractions until their behaviour has been checked against a reference preparation. “Digitalin” did not denote one uniform pure compound: a contemporary 1864 report distinguished preparations with markedly different solubilities. Accordingly, a negative result after one solvent partition is inconclusive; it would be particularly misleading to assume that the substance must follow the acid–base extraction behaviour of a simple alkaloid.^[ref]

Colour reactions could support the examination of a cleaned extract. Contemporary work described a brown or reddish colour with sulfuric acid, changed to violet by bromine vapour; the hydrochloric-acid green colour was already acknowledged to lack specificity. Compare a reference and a blank under the same conditions. Colour in a dirty stomach extract is not an identification, and tasting an unknown extract is not an acceptable analytical test.^[ref]

A particularly relevant development available before this examination was the physiological test investigated by Charles Hilton Fagge and Thomas Stevenson in 1865. An extracted fraction was compared with known digitalin using the response of a frog's heart. The informative effect was irregular beating followed by arrest with the cardiac ventricle pale and firmly contracted, rather than mere illness or death. Crucially, their experiments also showed that ordinary human stomach contents could injure frogs, and other cardiac poisons could resemble digitalin. A solvent blank, a comparable unpoisoned extract and a reference poison therefore matter. These are historical experiments, not a proposal to repeat animal testing for this solution.^[ref][ref]

The defensible conclusion combines extraction behaviour, chemical reactions, physiological specificity and the clinical circumstances, acknowledging uncertainty if these disagree. A modern laboratory would instead seek specific validated instrumental identification, for example chromatography coupled to mass spectrometry for an identified cardiac glycoside, with reference material and controls. That later capability must not be credited to an 1866 examiner.^[ref]

The sound historical indication was selected dropsical states associated with disordered cardiac action; the modern uses of particular cardiac glycosides are narrower and explicitly rhythm-dependent. A digitalis preparation was not simply a drug for every slow urinary flow or rapid pulse.

Before 1866, William Withering's account had already demonstrated both the possible relief of dropsy and the danger of careless use. He recorded successes and failures and warned about nausea, vomiting, visual disturbance and excessive slowing of the pulse. These observations support careful assessment of effect and toxicity, not a method of administering foxglove until poisoning occurs.^[ref] The historical assessment would follow breathing, swelling, pulse, urine and general condition. Increased urine and reduced oedema could represent relief while the original cardiac disorder persisted.

Calling the drug a cardiac “sedative” from the slowing of the pulse could obscure a different effect on contraction. Likewise, apparent diuresis did not establish it as a universal remedy for renal dropsy. Period applications extended into febrile or haemorrhagic illnesses, but such claims should not be promoted into modern indications merely because the pulse changed. The problem is to distinguish treatment of a useful physiological target from suppression of a sign.

Modern correction: digoxin increases myocardial contractility and slows conduction through the atrioventricular node. In selected heart failure it can improve symptoms and reduce hospitalization. A randomized, placebo-controlled trial in people with chronic heart failure and normal sinus rhythm found fewer hospitalizations but no reduction in overall mortality.^[ref] It can also control resting ventricular rate in selected adults with chronic atrial fibrillation. It is not a general treatment for a fast pulse, and the presence of an accessory conduction pathway can make its use hazardous. Ventricular fibrillation is a contraindication.^[ref]

The margin between useful and toxic exposure is small. Renal function, age, body composition, interactions and electrolyte disturbances influence risk. Monitor the clinical response, electrocardiogram, relevant laboratory results and drug concentrations when indicated. Nausea, vomiting, visual symptoms, marked bradycardia or new cardiac arrhythmias should raise concern for toxicity, not be treated as confirmation that the drug is beginning to work.^[ref] Historical leaf or tincture preparations must therefore not be substituted for a modern standardized preparation, or converted into modern doses from a shared name alone.